June 17, 2020 / 11:29 AM / 23 days ago

BRIEF-FDA Approves Second Biomarker-Based Indication For Merck's Keytruda

June 17 (Reuters) - Merck & Co Inc:

* FDA APPROVES SECOND BIOMARKER-BASED INDICATION FOR MERCK’S KEYTRUDA® (PEMBROLIZUMAB), REGARDLESS OF TUMOR TYPE

* MERCK & CO INC - KEYTRUDA IS NOW APPROVED FOR ADULT AND PEDIATRIC PATIENTS WITH UNRESECTABLE OR METASTATIC TUMOR MUTATIONAL BURDEN-HIGH SOLID TUMORS

* MERCK & CO- SAFETY, EFFECTIVENESS OF KEYTRUDA IN PEDIATRIC PATIENTS WITH TMB-H CENTRAL NERVOUS SYSTEM CANCERS NOT BEEN ESTABLISHED

* MERCK & CO INC - SECOND BIOMARKER-BASED INDICATION IS APPROVED UNDER ACCELERATED APPROVAL BASED ON TUMOR RESPONSE RATE AND DURABILITY OF RESPONSE Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below